• Sample Page
  • Home
  • Second Level
  • Investors
  • About
  • Stock Information
  • News Releases
  • SEC Filings
  • Analyst Coverage
  • Events and Presentations
  • Corporate Governance
  • Investor Contacts
  • Backgrounders
  • In the News
  • Images
  • Careers
  • Technology
  • Pipeline
  • Collaborations
  • Privacy Policy
  • Terms and Conditions of Use
  • Testtesttest
  • Collaborations

    Agenus is focused in immuno-oncology. However, our technologies and pipeline of molecules have the ability to treat other immune-mediated diseases outside of oncology.  We are advancing multiple product candidates in the clinic and defining the most suitable patient populations that may benefit from our novel therapeutic approaches. Our antibody discovery platforms are designed for the rapid screening and high throughput selection of optimized fully human antibodies that may be individually functionally equivalent to the best-in-class or may have both functional and therapeutic advantages. We have used these platforms to develop a range of checkpoint antibodies, a number of which are in clinical development and others which are expected to enter the clinic in the near term.  In addition, through our vaccine platforms we are pioneering both individualized and off-the-shelf vaccines.

    We are actively pursuing a variety of partnership opportunities to augment our internal programs. Key benefits of working with Agenus include:

    • Fully integrated research and development capabilities with 150 scientists across various disciplines
    • An extensive pipeline of checkpoint antibodies, vaccines and vaccine adjuvants with state of the art discovery platforms for each
    • State of the art cell line development capabilities
    • GMP manufacturing capabilities in antibodies and vaccines with an experienced operations team with a highly successful track record
    • Business development & commercial experience
    • Public company infrastructure
    • Over 20 years of clinical development expertise
    • Successful partnerships with Merck, GSK and Incyte with timely record of delivery
    • Extensive research partnerships with leading academic labs worldwide

    Agenus is advancing multiple immuno-oncology product candidates in the clinic